- Home
- NEN vs INBX Comparison
NEN vs INBX Comparison
Compare NEN & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEN
- INBX
- Stock Information
- Founded
- NEN 1977
- INBX 2010
- Country
- NEN United States
- INBX United States
- Employees
- NEN N/A
- INBX N/A
- Industry
- NEN Building operators
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- NEN Real Estate
- INBX Health Care
- Exchange
- NEN Nasdaq
- INBX Nasdaq
- Market Cap
- NEN 282.1M
- INBX 218.9M
- IPO Year
- NEN N/A
- INBX 2020
- Fundamental
- Price
- NEN $80.19
- INBX $13.92
- Analyst Decision
- NEN
- INBX Hold
- Analyst Count
- NEN 0
- INBX 1
- Target Price
- NEN N/A
- INBX N/A
- AVG Volume (30 Days)
- NEN 121.0
- INBX 81.4K
- Earning Date
- NEN 01-01-0001
- INBX 11-14-2024
- Dividend Yield
- NEN 1.99%
- INBX N/A
- EPS Growth
- NEN 67.91
- INBX N/A
- EPS
- NEN 3.91
- INBX 119.38
- Revenue
- NEN $81,169,352.00
- INBX $1,568,000.00
- Revenue This Year
- NEN N/A
- INBX N/A
- Revenue Next Year
- NEN N/A
- INBX N/A
- P/E Ratio
- NEN $20.63
- INBX $0.12
- Revenue Growth
- NEN 10.81
- INBX 19.24
- 52 Week Low
- NEN $67.04
- INBX $10.80
- 52 Week High
- NEN $84.00
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- NEN 38.67
- INBX 38.33
- Support Level
- NEN $82.10
- INBX $14.53
- Resistance Level
- NEN $82.74
- INBX $15.24
- Average True Range (ATR)
- NEN 0.08
- INBX 0.72
- MACD
- NEN -0.29
- INBX -0.10
- Stochastic Oscillator
- NEN 0.00
- INBX 19.16
About NEN New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership
New England Realty Associates LP is engaged in the business of acquiring, developing, holding for investment, operating and selling real estate. The Partnership owns and operates various residential apartments, condominium units and commercial properties located in Massachusetts and New Hampshire. The company generates revenue from rental income from residential and commercial properties recognized over the term of the related lease. The long-term goals of the Partnership are to manage, rent and improve its properties and to acquire additional properties with income and capital appreciation potential as suitable opportunities arise.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.